About Hemicentin-2
Hemicentin-2 (HMCN2) is a protein
from Homo sapiens identified by UniProt accession
Q8NDA2, 5079 residues long.
MolForge cross-references it against 0 known binders and
54 disease associations.
Target properties
| Protein name | Hemicentin-2 |
|---|
| UniProt accession | Q8NDA2 |
|---|
| Gene | HMCN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 5079 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (54)
Diseases linked to this target (Open Targets).
- aspartate aminotransferase measurement · score 0.34
- diverticular disease · score 0.33
- electrocardiography · score 0.32
- neurodegenerative disease · score 0.23
- cystatin C measurement · score 0.18
- metabolite measurement · score 0.18
- laryngeal neoplasm · score 0.12
- Tinnitus · score 0.06
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.06
- Blackfan-Diamond anemia · score 0.06
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (5079 residues)
MMPGAPLLRL LTAVSAAVAV AVAGAPGTVM PPTTGDATLA FVFDVTGSMW DELMQVIDGA SRILERSLSR RSQAIANYAL VPFHDPDIGP VTLTADPTVF QRELRELYVQ GGGDCPEMSV GAIKAAVEVA NPGSFIYVFS DARAKDYHKK EELLRLLQLK QSQVVFVLTG DCGDRTHPGY LAYEEIAATS SGQVFHLDKQ QVTEVLKWVE SAIQASKVHL LSTDHEEEGE HTWRLPFDPS LKEVTISLSG PGPEIEVQDP LGRILQEDEG LNVLLNIPDS AKVVAFKPEH PGLWSIKVYS SGRHSVRITG VSNIDFRAGF STQPLLDLNH TLEWPLQGVP ISLVINSTGL KAPGRLDSVE LAQSSGKPLL TLPTKPLSNG STHQLWGGPP FHTPKERFYL KVKGKDHEGN PLLRVSGVSY SGVAPGAPLV SMAPRIHGYL HQPLLVSCSV HSALPFRLQL RRGEARLGEE RHFQESGNSS WEILRASKAE EGTYECTAVS RAGTGRAKAQ IVVTDPPPQL VPAPNVTVSP GETAVLSCRV LGEAPYNLTW VRDWRVLPAS TGRVAQLADL SLEISGIIPT DGGRYQCVAS NANGVTRASV WLLVREAPQV SIHTSSQHFS QGVEVKVSCS ASGYPTPHIS WSRESQALQE DSRIHVDAQG TLIIQGVAPE DAGNYSCQAT NEVGTDQETV TLYYTDPPSV SAVNAVVLVA VGEEAVLVCE ASGVPPPRVI WYRGGLEMIL APEGSSSGKL RIPAAQERDA GTYTCRAVNE LGDASAEIQL AVGHAPQLTE LPRDVTVELG RSALLACRAT GRPPPTVTWR RGDGQPLGLR LGAGRGSRSR QPDSGVLFFE SVAPEDQAPY VCEARNVFGK VQAEARLIVT GHAPPQIASS APTVRVLEGQ PVSLPCIVLA GRPLPERHWL KDGRPLPPGS RHSIRADGSL HLDRALQEHA GRYSCVATNT AGSQHRDVEL VVQVPPRIHP TATHHITNEG VAASLPCVAS GVPAPTITWT KETNALTSRG PHYNVSKEGT LLIAQPSAQD AGAYVCTATN TVGFSSQEMR LSVNTKPRIH MNGSRNADVP LQVTAKAGEE VTLDCEAKGS PPPLVTWTKD SRPVPPITNR YGLLPSGSLR LAQVQVGDSG HYECTASNPA GSASHRYVLG VQVPPQVQPG PRVLKVLVGE ALDLNCVAEG NPEPQLSWSK DGVVLQGRGP QGSVHFAAIR TSDAGRYRCE ASNSAGVDAW EVELRVLEPP HWGADETSGL LERVAGENAS LPCPARGTPK PQVTWRKGPS SEPLHGQPGV AVLEEGSLFL ASVSPADSGD YECQATNEVG STSRRAKLVV YVPPSIREDG RKANVSGMAG QSLTLECDAN GFPVPEIVWL KDAQLIPKVG GHRLLDEGQS LHFPRIQEGD SGLYSCRAEN QAGTAQRDFH LLVLTPPSVL GAGAAQEVLG LAGADVELQC WTSGVPTPQV EWTKDRQPVL PGGPHLQVQE DGQVLRITGS HVGDEGRYQC VAFSPAGQQA RDFQLRVHAP PTIWGSNETG EVAVMEDHLV QLLCEARGVP TPNITWFKDG ALLPTSTKVV YTRGGRQLQL GRAQSSDAGV YTCKASNAVG AAEKATRLDV YVPPTIEGAG GRPYVVKAVA GRPVALECVA RGHPSPTLSW HHEGLPVAES NESRLETDGS VLRLESPGEA SSGLYSCVAS SPAGEAVLQY SVEVQVPPQL LVAEGLGQVT TIVGQPLELP CQASGSPVPT IQWLQNGRPA EELAGVQVAS QGTTLHIDHV ELDHSGLFAC QATNEAGTAG AEVEVSVHEF PSVSIIGGEN ITAPFLQPVT LQCIGDGVPT PSLRWWKDGV ALAAFGGNLQ IEKVDLRDEG IYTCAATNLA GESKREVALK VLVPPNIEPG PVNKAVLENA SVTLECLASG VPPPDVSWFK GHQPVSSWMG VTVSVDGRVL RIEQAQLSDA GSYRCVASNV AGSTELRYGL RVNVPPRITL PPSLPGPVLV NTPVRLTCNA TGAPSPTLMW LKDGNPVSPA GTPGLQVFPG GRVLTLASAR ASDSGRYSCV AVSAVGEDRQ DVVLQVHMPP SILGEELNVS VVANESVALE CQSHAMPPPV LSWWKDGRPL EPRPGVHLSA DKALLQVDRA DVWDAGHYTC EALNQAGHSE KHYNLNVWVA PVFPLRESHT LTVREGHPTR LSCECRGVPF PKISWRKDGQ PLPGEGAGLQ HVSAVGRLLY LGQAQLAQEG TYTCECSNVV GNSSQDLQLE VHVPPQIAGP REPPTQVSVV QDGVATLECN ATGKPPPTVT WERDGQPVGA ELGLQLQNQG QSLHVERAQA AHTGRYSCVA ENLAGRAERK FELSVLVPPE LIGDLDPLTN ITAALHSPLT LLCEAMGIPP PAIRWFRGEE PVSPGEDTYL LAGGWMLKMT QTQEQDSGLY SCLASNEAGE ARRNFSVEVL VPPSIENEDL EEVIKVLDGQ TAHLMCNVTG HPQPKLTWFK DGRPLARGDA HHISPDGVLL QVLQANLSSA GHYSCIAANA VGEKTKHFQL SVLLAPTILG GAEDSADEEV TVTVNNPISL ICEALAFPSP NITWMKDGAP FEASRNIQLL PGTHGLQILN AQKEDAGQYT CVVTNELGEA VKNYHVEVLI PPSISKDDPL AEVGVKEVKT KVNSTLTLEC ESWAVPPPTI RWYKDGQPVT PSSRLQVLGE GRLLQIQPTQ VSDSGRYLCV ATNVAGEDDQ DFNVLIQVPP MFQKVGDFSA AFEILSREEE ARGGVTEYRE IVENNPAYLY CDTNAIPPPD LTWYREDQPL SAGDEVSVLQ GGRVLQIPLV RAENAGRYSC KASNEVGEDW LHYELLVLTP PVILGDTEEL VEEVTVNASS TVSLQCPALG NPVPTISWLQ NGLPFSPSPR LQVLEDGQVL QVSTAEVADA ASYMCVAENQ AGSAEKLFTL RVQVPPRIAG LDLEQVTAIL NSSVSLPCDV HAHPNPEVTW YKDSQALSLG EEVFLLPGTH TLQLGRARLS DSGMYTCEAL NAAGRDQKLV QLSVLVPPAF RQAPRGPQDA VLVRVGDKAV LSCETDALPE PTVTWYKDGQ PLVLAQRTQA LRGGQRLEIQ EAQVSDKGLY SCKVSNVAGE AVRTFTLTVQ VPPTFENPKT ETVSQVAGSP LVLTCDVSGV PAPTVTWLKD RMPVESSAVH GVVSRGGRLQ LSRLQPAQAG TYTCVAENTQ AEARKDFVVA VLVAPRIRSS GVAREHHVLE GQEVRLDCEA DGQPPPDVAW LKDGSPLGQD MGPHLRFYLD GGSLVLKGLR ASDAGAYTCV AHNPAGEDAR LHTVNVLVPP TIKQGADGSG TLVSRPGELV TMVCPVRGSP PIHVSWLKDG LPLPLSQRTL LHGSGHTLRI SKVQLADAGI FTCVAASPAG VADRNFTLQV QVPPVLEPVE FQNDVVVVRG SLVELPCEAR GVPLPLVSWM KDGEPLLSQS LEQGPSLQLE AVGAGDSGTY SCVAVSEAGE ARRHFQLTVM EPPHIEDSGQ PTELSLTPGA PMELLCDAQG TPQPNITWHK DGQALTRLEN NSRATRVLRV ENVQVRDAGL YTCLAESPAG AIEKSFRVRV QAPPNIVGPR GPRFVVGLAP GQLVLECSVE AEPAPKITWH RDGIVLQEDA HTQFPERGRF LQLQALSTAD SGDYSCTARN AAGSTSVAFR VEIHTVPTIR SGPPAVNVSV NQTALLPCQA DGVPAPLVSW RKDRVPLDPR SPRFEILPEG SLRIQPVLAQ DAGHYLCLAS NSAGSDRQGR DLRVLEPPAI APSPSNLTLT AHTPALLPCE ASGSPKPLVV WWKDGQKLDF RLQQGAYRLL PSNALLLTAP GPQDSAQFEC VVSNEVGEAH RLYQVTVHVP PTIADDQTDF TVTMMAPVVL TCHSTGIPAP TVSWSKAGAQ LGARGSGYRV SPSGALEIGQ ALPIHAGRYT CSARNSAGVA HKHVFLTVQA SPVVKPLPSV VRAVAEEEVL LPCEASGIPR PTITWQKEGL NVATGVSTQV LPGGQLRIAH ASPEDAGNYL CIAKNSAGSA MGKTRLVVQV PPVIENGLPD LSTTEGSHAF LPCKARGSPE PNITWDKDGQ PVSGAEGKFT IQPSGELLVK NLEGQDAGTY TCTAENAVGR ARRRVHLTIL VLPVFTTLPG DRSLRLGDRL WLRCAARGSP TPRIGWTVND RPVTEGVSEQ DGGSTLQRAA VSREDSGTYV CWAENRVGRT QAVSFVHVKE APVLQGEAFS YLVEPVGGSI QLDCVVRGDP VPDIHWIKDG LPLRGSHLRH QLQNGSLTIR RTERDDAGRY QCLAENEMGV AKKVVILVLQ SAPVFQVEPQ DMTVRSGDDV ALRCQATGEP TPTIEWLQAG QPLRASRRLR TLPDGSLWLE NVETGDAGTY DCVAHNLLGS ATARAFLVVR GEPQGSWGSM TGVINGRKFG VATLNTSVMQ EAHSGVSSIH SSIRHVPANV GPLMRVLVVT IAPIYWALAR ESGEALNGHS LTGGRFRQES HVEFATGELL TMTQVARGLD PDGLLLLDVV VNGVVPESLA DADLQVQDFE EHYVQTGPGQ LFVGSTQRFF QGGLPSFLRC NHSIQYNAAR GPQPQLVQHL RASAISSAFD PEAEALRFQL ATALQAEENE VGCPEGFELD SQGAFCVDRD ECSGGPSPCS HACLNAPGRF SCTCPTGFAL AWDDRNCRDV DECAWDAHLC REGQRCVNLL GSYRCLPDCG PGFRVADGAG CEDVDECLEG LDDCHYNQLC ENTPGGHRCS CPRGYRMQGP SLPCLDVNEC LQLPKACAYQ CHNLQGSYRC LCPPGQTLLR DGKACTSLER NGQNVTTVSH RGPLLPWLRP WASIPGTSYH AWVSLRPGPM ALSSVGRAWC PPGFIRQNGV CTDLDECRVR NLCQHACRNT EGSYQCLCPA GYRLLPSGKN CQDINECEEE SIECGPGQMC FNTRGSYQCV DTPCPATYRQ GPSPGTCFRR CSQDCGTGGP STLQYRLLPL PLGVRAHHDV ARLTAFSEVG VPANRTELSM LEPDPRSPFA LRPLRAGLGA VYTRRALTRA GLYRLTVRAA APRHQSVFVL LIAVSPYPY
Explore Hemicentin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets